Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
Ulcerative colitis patients treated with Infliximab (IFX) in deep remission after at least 12 months of treatment will be randomized to continue IFX or to stop IFX and start Azathioprine (AZA). Each patient will be followed for 12 months.
Epistemonikos ID: 32d80b59052989e59b23114713deb464410b8ab7
First added on: Mar 23, 2022